DBV Technologies S.A. (DBVT) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
DBV Technologies S.A. (DBVT) has outperformed Valneva (VALN) over the past year, losing 34.4% versus a loss of 40.1%. Over five years, DBVT leads with a +50.3% price change compared with -91.3% for VALN. DBV Technologies S.A. is the larger company by market cap ($566.8 million vs $490.9 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | VALN |
|---|---|---|
| Share price | $9.02 | $5.16 |
| Market cap | $566.82M | $490.86M |
| 1-day change | -4.25% | -3.82% |
| YTD return | -52.95% | -41.50% |
| 1-year return | -34.40% | -40.14% |
| 5-year return | +50.33% | -91.34% |
| Forward P/E | — | 4.34 |
| EPS (TTM) | $-3.00 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.64M | — |
| Revenue growth (YoY) | +35.77% | — |
| Net income (latest FY) | $-146.95M | — |
| Operating margin | -2609.23% | — |
| Net margin | -2607.29% | — |
| 52-week high | $26.19 | $12.18 |
| 52-week low | $8.63 | $4.75 |
| Distance from 52-week high | -65.55% | -57.64% |
| Analyst consensus | buy | none |
| Avg. price target upside | +305.10% | +137.98% |
| Average volume | 352.88K | 23.10K |
| Shares outstanding | 62.84M | 95.13M |
| Employees | 179 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 179 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
DBVT vs VALN FAQ
Which is bigger, DBV Technologies S.A. or Valneva?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $566.82M compared with $490.86M for Valneva (VALN).
Which stock has performed better over the past year, DBVT or VALN?
DBVT returned -34.40% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are DBV Technologies S.A. and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.